Fig. 5: AXL inhibition attenuates the metastasis of MG63.2 OS cell lines. | Cancer Gene Therapy

Fig. 5: AXL inhibition attenuates the metastasis of MG63.2 OS cell lines.

From: Transcriptional activators YAP/TAZ and AXL orchestrate dedifferentiation, cell fate, and metastasis in human osteosarcoma

Fig. 5

A Preclinical experiment design. B Monitoring OS tumor growth in lung and SGI-7079 (AXL inhibitor, AXLi) treatment response after tail vein injection of MG63/MG63.2-luciferase cell lines in immunodeficient mice. The luminescent intensity of photons emitted from each tumor from control and AXLi-treated mice after injections with 5 × 105 luciferase- MG63/MG63.2 cells. C Bioluminescent imaging of mice 25 days post-tail vein injection of 5 × 105 MG63.2-expressing luciferase during AXLi and placebo treatments. D Quantification of pulmonary metastatic nodules in MG63 and MG63.2 xenograft mice after AXLi and placebo treatments. E IHC stains for AXL and vimentin in lung tissues of MG63.2 xenograft mice after AXLi or placebo treatments. F Western blot analyses of AXL and pAXL expression in lung tissues of MG63.2 xenograft mice after AXLi or placebo treatments (left panel). Normalized AXL and pAXL expression relative to GAPDH in lung tissues of MG63.2 xenograft mice after AXLi or placebo treatments (right panel) with unpaired two-tailed Student’s t test statistical analyses; bars show mean ± SD.

Back to article page